- Home
- CRUS vs MDGL Comparison
CRUS vs MDGL Comparison
Compare CRUS & MDGL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CRUS
- MDGL
- Stock Information
- Founded
- CRUS 1984
- MDGL 2011
- Country
- CRUS United States
- MDGL United States
- Employees
- CRUS N/A
- MDGL N/A
- Industry
- CRUS Semiconductors
- MDGL Biotechnology: Pharmaceutical Preparations
- Sector
- CRUS Technology
- MDGL Health Care
- Exchange
- CRUS Nasdaq
- MDGL Nasdaq
- Market Cap
- CRUS 5.5B
- MDGL 6.1B
- IPO Year
- CRUS 1989
- MDGL N/A
- Fundamental
- Price
- CRUS $104.87
- MDGL $314.31
- Analyst Decision
- CRUS Strong Buy
- MDGL Strong Buy
- Analyst Count
- CRUS 5
- MDGL 9
- Target Price
- CRUS $126.40
- MDGL $420.63
- AVG Volume (30 Days)
- CRUS 515.4K
- MDGL 282.4K
- Earning Date
- CRUS 08-05-2025
- MDGL 08-06-2025
- Dividend Yield
- CRUS N/A
- MDGL N/A
- EPS Growth
- CRUS 22.45
- MDGL N/A
- EPS
- CRUS 6.00
- MDGL N/A
- Revenue
- CRUS $1,896,077,000.00
- MDGL $317,383,000.00
- Revenue This Year
- CRUS N/A
- MDGL $286.17
- Revenue Next Year
- CRUS $7.88
- MDGL $64.17
- P/E Ratio
- CRUS $17.36
- MDGL N/A
- Revenue Growth
- CRUS 5.99
- MDGL N/A
- 52 Week Low
- CRUS $75.83
- MDGL $200.63
- 52 Week High
- CRUS $147.46
- MDGL $377.46
- Technical
- Relative Strength Index (RSI)
- CRUS 49.03
- MDGL 64.53
- Support Level
- CRUS $102.33
- MDGL $284.02
- Resistance Level
- CRUS $111.48
- MDGL $311.21
- Average True Range (ATR)
- CRUS 2.83
- MDGL 11.94
- MACD
- CRUS -0.40
- MDGL 2.74
- Stochastic Oscillator
- CRUS 24.10
- MDGL 100.00
About CRUS Cirrus Logic Inc.
Cirrus Logic Inc is a provider of integrated circuits for audio and voice signal processing applications. The firm's products are organized into two streams: portable audio products, and HPMS Products. These products include aAmplifiers, codecs, smart codecs, analog-to-digital converters, digital-to-analog converters and standalone digital signal processors, Camera controllers, haptics and sensing solutions, and battery and power ICs. Roughly half of the firm's revenue is generated in China, with the rest coming from the United States, Europe, South Korea, and countries across the world.
About MDGL Madrigal Pharmaceuticals Inc.
Madrigal Pharmaceuticals Inc is a biopharmaceutical company focused on delivering novel therapeutics for metabolic dysfunction-associated steatohepatitis (MASH), a serious liver disease with high unmet medical need that can lead to cirrhosis, liver failure, and premature mortality. The company's medication, Rezdiffra (resmetirom), is a once-daily, oral, liver-directed thyroid hormone receptor agonist designed to target key underlying causes of MASH.